The major goals of the Southwest oncology genitourinary (SWOG-GU) committee in the area of advanced prostate cancer are to improve the survival and quality of life (QOL) of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.
Banerjee, S., Hussain, M., Wang, Z., Saliganan, A., Che, M., Bonfil, D. et al. (2007) In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res67: 3818-26.
2.
Beer, T.M., Goldman, B., Synold, T.W., Ryan, C.W., Vasist, L.S., VanVeldheusin Jr, P.J. et al. (2008) Southwest oncology group phase II study of ispenesib in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer6: 103-9.
3.
Beer, T.M., Tangen, C.M., Bland, L.B., Hussain, M., Goldman, B.H., deLoughery, T.G. et al. (2006) The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer. Cancer107: 489-96.
4.
Berruti, A., Fara, E., Tucci, M., Tarabuzzi, R., Mosca, A., Terrone, C. et al. (2005) Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up. Urol Oncol23: 1-7.
5.
Berry, D.L., Moinpour, C.M., Jiang, C.S., Ankerst, D.P., Petrylak, D.P., Vinson, L.V. et al. (2008) Quality of life and pain in advanced stage prostate cancer: results of a southwest oncology group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol24: 2828-35.
6.
Bhandari, M.S., Crook, J. and Hussain, M. ( 2005) Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol32: 8212-18.
7.
Bruchovsky, N., Rennie, P.S., Coldman, A.J., Goldenberg, S.L., To, M. and Lawson, D. ( 1990) Effects of androgen withdrawl on the stem cell composition of the Shionogi carcinoma. Cancer Res50: 2275-83.
8.
Caldiroli, M., Cova, V., Lovisolo, J.A., Reali, L. and Bono, A.V. ( 2001) Antiandrogen withdrawl in the treatment of hormone-relapsed prostate cancer: single institutional experience. Eur Urol39: 6-10.
9.
Carducci, M.A., Padley, R.J., Breul, J., Vogelzang, N.J., Zonnenberg, B.A., Daliani, D.D. et al. (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol21: 679-89.
10.
Carducci, M.A., Saad, F., Abrahamsson, P.A., Dearnaley, D.P., Schulman, C.C., North, S.A. et al. (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer110: 1959-66.
11.
Chung, L.W.K., Baseman, A., Assikis, V. and Zhau, H.E. ( 2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol173: 10-20.
12.
Chung, T.D.K., Yu, J.J., Spiotto, M.T., Bartkowski, M. and Simons, J.W. ( 1999) Characterization of the role of IL-6 in the progression of prostate cancer. Prostate38: 199-207.
13.
Crawford, E.D., Eisenberger, M.A., McLeod, D.G., Spaulding, J.T., Benson, R., Dorr, F.A. et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl J Med321: 419-24.
14.
De Bono, J.S., Scher, H.I., Montgomery, R.B., Parker, C., Miller, M.C., Tissing, H. et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res14: 6302-09.
15.
Del Bufalo, D., Di Castro, V., Biroccio, A., Salani, D., Rosano, L., Trisciuoglio, D. et al. (2002) Endothelin-1 protects ovarian cancer cells against paclitaxel-induced apoptosis: requirement for akt activation. Mol Pharmacol61: 524-32.
16.
Dimopoulos, M.A., Panopoulos, C., Bamia, C., Deliveliotis, C., Alivizatos, G., Pantazopoulos, Z. et al. (1997) Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology50: 754-8.
17.
Eigl, B.J., Eggener, S.E., Baybik, J., Ettinger, S., Chi, K.N., Nelson, C. et al. (2005) Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cacner. Clin Cancer Res11: 4905.
18.
Eisenberger, M.A., Blumenstein, B.A., Crawford, E.D., Miller, G., McLeod, D.G., Loehrer, P.J. et al. (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New Engl J Med339: 1036-42.
19.
Feldman, B.J. and Feldman, D. ( 2001) The development of androgen-independent prostate cancer . Nat Rev Cancer1: 34-45.
20.
Geller, J., Albert, J., Loza, D., Geller, S. and Stoeltzing, W. ( 1978) DHT concentrations in human prostate cancer tissue . J Clin Endocrinol Metab46: 440-4.
21.
Goh, B.C., Lee, S.C., Wang, L.Z., Fan, L., Guo, J.Y., Lamba, J. et al. (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol20: 3683-90.
22.
Grossman, M.E., Huang, H. and Tindall, D.J. ( 2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst93: 1687-97.
23.
Huan, S.D., Gerridzen, R.G., Yau, J.C. and Stewart, D.J. ( 1997) Antiandrogen withdrawal syndrome with nilutamide . Urology49: 632-4.
24.
Huggins, C. ( 1942) Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg115: 1192-200.
25.
Hussain, M., Tangen, C.M., Lara, P.N., Vaishampayan, U.N., Petrylak, D.P., Colevas, A.D. et al. (2005) Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naïve patients with hormone-refractory prostate cancer: a southwest oncology group trial S0111. J Clin Oncol23: 8724-9.
26.
Hussain, M., Tangen, C.M., Higano, C., Schellhammer, P.F., Faulkner, J., Crawford, E.D. et al. (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol24: 3984-90.
27.
Hussain, M., Goldman, B., Tangen, C., Higano, C.S., Petrylak, D.P., Wilding, G. et al. (2009) Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from southwest oncology group trials 9346 (intergroup study 0162) and 9916. J Clin Oncol27: 2450-2456.
28.
Isaacs, J.T. and Coffey, D.S. ( 1991) Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res41: 5070-5.
29.
Jemal, A., Siegel, R., Ward, E., Murray, T., Hao, Y. et al. (2009) Cancer statistics. CA Cancer J Clin57: 225-249.
30.
Kantoff, P.W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V. et al. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol17: 2506-13.
31.
Keuppens, F., Whelan, P., Carneiro de Moura, J.L., Newling, D., Bono, A., Denis, L. et al. (1993) Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer - Genitourinary Group. Cancer72: 3863-9.
32.
Labrie, F., Dupont, A., Belanger, A., Giguere, M., Lacoursiere, Y., Emond, J. et al. (1985) Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in survival. J Steroid Biochem Mol Biol23: 833-41.
33.
Logothetis, C.J., Samuels, M.L., von Eschenbach, A.C., Trindade, A., Ogden, S., Grant, C. et al. (1983) Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate with a note on the staging of metastatic prostate cancer. J Clin Oncol1: 368-79.
34.
Montgomery, R.B., Goldman, B., Tangen, C.M., Hussain, M., Petrylak, D.P., Page, S. et al. (2007) Association of body mass index with response and survival in men with metastatic prostate cancer: southwest oncology group trials 8894 and 9916. J Urol178: 1946-51.
35.
Mostaghel, E.A., Page, S.T., Lin, D.W., Fazli, L., Coleman, I.M., True, L.D. et al. (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res67: 5033-41.
36.
Mukamel, E., Nissenkorn, I. and Servadio, C. ( 1980) Early combined hormonal and chemotherapy for metastatic carcinoma of prostate. Urology16: 257-60.
37.
Nelson, J.B., Nabulsi, A.A., Vogelzang, N.J., Breul, J., Zonnenberg, B.A., Daliani, D.D. et al. (2003) Suppression of prostate-cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol169: 1143-9.
38.
Oakley-Girvan, I., Kolonel, L.N., Gallagher, R.P., Wu, A.H., Felberg, A. and Whittemore, A.S. ( 2003) Stage at diagnosis and survival in a multi-ethnic cohort of prostate cancer patients. Am J Public Health93: 1753-9.
39.
Osborne, C.K., Blumenstein, B., Crawford, E.D., Coltman Jr, C.A., Smith, A.Y., Lambuth, B.W. et al. (1990) Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized southwest oncology group study. J Clin Oncol8: 1675-82.
40.
Petrylak, D.P., Ankerst, D.P., Jiang, C.S., Tangen, C.M., Hussain, M.H.A., Lara Jr, P.N. et al. (2006) Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst98: 516-21.
41.
Petrylak, D.P., Tangen, C.M., Hussain, M.H., Lara Jr, P.N., Jones, J.A., Taplin, M.E. et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone in advanced refractory prostate cancer. New Engl J Med351: 1513-20.
42.
Pienta, K.J., Fisher, E.I., Eisenberger, M.A., Mills, G.M., Goodwin, J.W., Jones, J.A. et al. (2001) A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: a southwest oncology group trial (SWOG 9407). Prostate46: 257-61.
43.
Pienta, K.J., Redman, B.G., Bandekar, R., Strawderman, M., Cease, K., Esper, P.S. et al. (1997) A phase II trial of oral estramustine and oral etoposide in hormone-refractory prostate cancer. Urology50: 401-7.
44.
Pinski, J. and Dorff, T.B. ( 2005) Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur J Cancer41: 932-40.
45.
Rosano, L., Spinella, F., Salani, D., Natali, P.G. and Bagnato, A. ( 2003) Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res63: 2447-53.
46.
Sartor, A.O., Tangen, C.M., Hussain, M.H.A., Eisenberger, M.A., Parab, M., Fontana, J.A. et al. (2008) Antiandrogen withdrawl in castrate-refractory prostate cancer. Cancer112: 2393-400.
47.
Savarese, D.M., Halabi, S., Hars, V., Akerley, W.L., Taplin, M.E., Godley, P.A. et al. (2001) Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol19: 2509-16.
48.
Schellhammer, P.F., Venner, P., Haas, G.P., Small, E.J., Nieh, P.T., Seabaugh, D.R. et al. (1997) Prostate specific antigen decreases after withdrawl of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol157: 1731-5.
49.
Small, E.J. and Srinivas, S. ( 1995) The antiandrogen withdrawl syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer76: 1428-34.
50.
Smith, D.C., Esper, P., Strawderman, M., Redman, B. and Pienta, K.J. ( 1999) Phase I trial of estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol17: 1664-71.
51.
Smith, P.C. and Keller, E.T. ( 2001) Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate48: 47-53.
52.
Sumiyoshi, Y., Hashino, K., Nakatsuzi, H., Yamashita, Y. and Karashima, T. ( 2000) Oral estramustine phosphate and oral etoposide for the treatment of hormnone-refractory prostate cancer. Int J Urol7: 243-7.
53.
Sweeney, C.J. ( 2006) ECOG: CHAARTED - chemohormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clin Adv Hematol Oncol4: 588-90.
54.
Tannock, I.F., Osoba, D., Stockler, M.R., Ernst, D.S., Neville, A.J., Moore, M.J. et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol14: 1756-64.
55.
Tannock, I.F., deWit, R., Berry, W.R., Horti, J., Pluzanska, A., Chi, K.N. et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med351: 1502-12.
56.
Torti, F.M., Aston, D., Lum, B.L., Kohler, M., Williams, R., Spaulding, J.T. et al. (1983) Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol1: 477-82.
57.
Tyrrell, C.J., Altwein, J.E., Klippel, F., Varenhorst, E., Lunglmayr, G., Boccardo, F. et al. (1993) Multicenter randomized trial comparing zoladex with zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. The International Prostate Cancer Study Group. Cancer72: 3878-9.
